NMNAT1 and inflammatory bowel disease: Disease- and treatment-related changes in NAD+ levels were independent of nicotinamide nucleotide adenylyltransferase 1 (NMNAT1) activity, as its expression was not altered in IBD nor was it affected by infliximab (Figure 4).